AR056205A1 - Antagonistas de receptores cgrp, composiciones farmaceuticas que los contienen, metodo de preparacion y usos para el tratamiento agudo y preventivo de dolores de cabeza, en particular migranas, y otras enfermedades - Google Patents

Antagonistas de receptores cgrp, composiciones farmaceuticas que los contienen, metodo de preparacion y usos para el tratamiento agudo y preventivo de dolores de cabeza, en particular migranas, y otras enfermedades

Info

Publication number
AR056205A1
AR056205A1 ARP060104297A ARP060104297A AR056205A1 AR 056205 A1 AR056205 A1 AR 056205A1 AR P060104297 A ARP060104297 A AR P060104297A AR P060104297 A ARP060104297 A AR P060104297A AR 056205 A1 AR056205 A1 AR 056205A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
group
formula
cycloalkyl
Prior art date
Application number
ARP060104297A
Other languages
English (en)
Inventor
Klaus Rudolf
Philipp Lustenberger
Dirk Stenkamp
Marco Santagostino
Fabio Paleari
Henri Doods
Kirsten Arndt
Gerhard Schaenzle
Stephan Georg Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR056205A1 publication Critical patent/AR056205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Antagonistas de CGRP de la formula general (1) en la que R1 significa un grupo seleccionado entre los compuestos de formula (2), (3) y (4), en los que R1.1 representa H o H3C-O-; R2 significa un grupo de la formula general (5) en los que R2.1 es HO- , H3CO-, H-C(O)-O o H3C-C(O)-O y R2.2 es alquilo C1-2- o H3CO-; R3 es R4-alquilen C2-8-NH- y R4 es H, H2N-, alquilo C1-3-NH-, (alquil C1-3)2-N- o alquil C1-6-O-C(O)-NH-; o R3 significa un grupo de las formulas generales (6) en las que R3.2 es H o alquilo C1-3-, R3.3 es un par de electrones libres o un átomo de oxígeno, R3.4 es H o alquilo C1-3- y R4 es H, alquilo C1-6-, H2N-alquileno C1-6-, alquil C1-3-NH-alquileno C1-6-, (alquil C1-3)2 -N-alquileno C1-6-, cicloalquil C3-6-alquileno C1-6-, NH2-, alquil C1-3-NH- o (alquil C1-3)2-N-, o R4 significa un grupo seleccionado de los radicales del grupo de formulas (7), o R4 un resto seleccionado del grupo de las formulas generales (8) en los que X es C y R4.1 es H, OH o alquilo C1-3, o X es N y R4.1 es un par de electrones libres o un átomo de oxígeno; Y es O, S, S(O), S(O)2, cuando X = N, o Y es S, S(O), S(O)2, cuando X = C; R4.2 es H o alquilo C1-3-, R4.3 es H o alquilo C1-3-, R4.4 es un par de electrones libres o cuando R5.2 no es H o alquil C1-3-C(O)-, un átomo de oxígeno; R5.1 es H, CN, OH, alquilo C1-3-, alquil C1-3-C(O)-O-, alquil C1-3-O-, R5.1.1-O-C(O)-, R5.1.1-O-C(O)-alquilen C2-4 o R5.1.1-O-C(O)-alquilen C1-3-O-; R5.1.1 es H, alquilo C1-6-, H2N-C(O)-alquileno C1-3-, alquil C1-3-NH-C(O)-alquileno C1-3-, (alquil C1-3)2-N-C(O)-alquileno C1-3 o alquil C1-3-O-C(O)-O-alquileno C1-3-; R5.2 es H, alquilo C1-3-, cicloalquilo C3-6-, cicloalquil C3-6-alquileno C1-3-, alquil C1-3-C(O)-, R5.2.1-O-C(O)-alquileno C1-3 o R5.2.2- alquilen C2-4-O-C(O)-alquileno C1-3-; R5.2.1 es H, alquilo C1-6-, alquil C1-6-C(O)-O-alquileno C1-3-, alquil C1-3-O-C(O)-O-alquileno C1-3-, cicloalquil C3-7-O-C(O)-O-alquileno C1-3-, H2N-C(O)-alquileno C1-3-, alquil C1-3-NH-C(O)-alquileno C1-3-, (alquil C1-3)2-N-C(O)-alquileno C1-3 o R5.2.1.1-C(O)-alquileno C1-3 y R5.2.1.1 es un grupo seleccionado del par de radicales del grupo de formulas (9) o R5.2.1 es un grupo seleccionado de los radicales del grupo de formulas (10); R5.2.2 es H2N, alquil C1-3-NH-, (alquil C1-3)2-N-, alquil C1-3-O- o alquil C1-3-O-alquilen C2-4-O-, o R5.2.2 es un resto seleccionado de los radicales del grupo de formulas (11), con la condicion de que R3 y R4 no estén unidos entre sí al mismo tiempo a través de un átomo de N, sus tautomeros, sus diastereoisomeros, sus enantiomeros, sus hidratos, sus mezclas y sus sales, en particular sus sales fisiologicamente compatibles con ácidos o bases inorgánicos u orgánicos.
ARP060104297A 2005-09-29 2006-09-29 Antagonistas de receptores cgrp, composiciones farmaceuticas que los contienen, metodo de preparacion y usos para el tratamiento agudo y preventivo de dolores de cabeza, en particular migranas, y otras enfermedades AR056205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05021236A EP1770086A1 (de) 2005-09-29 2005-09-29 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR056205A1 true AR056205A1 (es) 2007-09-26

Family

ID=36102594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104297A AR056205A1 (es) 2005-09-29 2006-09-29 Antagonistas de receptores cgrp, composiciones farmaceuticas que los contienen, metodo de preparacion y usos para el tratamiento agudo y preventivo de dolores de cabeza, en particular migranas, y otras enfermedades

Country Status (13)

Country Link
US (2) US7582625B2 (es)
EP (2) EP1770086A1 (es)
JP (1) JP2009510022A (es)
KR (1) KR20080056252A (es)
CN (1) CN101273021A (es)
AR (1) AR056205A1 (es)
AU (1) AU2006296541A1 (es)
CA (1) CA2623156A1 (es)
IL (1) IL190423A0 (es)
RU (1) RU2008116320A (es)
TW (1) TW200800922A (es)
WO (1) WO2007036532A2 (es)
ZA (1) ZA200800431B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
ES2429443T3 (es) * 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
PE20080153A1 (es) * 2006-06-08 2008-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
DE102007038251A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
WO2010070023A2 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
KR101643797B1 (ko) 2009-06-24 2016-07-28 스트러티직 사이언스 앤드 테크놀로지스, 엘엘씨 이부프로펜을 함유하는 국소 조성물
JP2014504592A (ja) 2010-12-29 2014-02-24 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 勃起不全および他の適応症の処置
US20140010866A1 (en) * 2010-12-29 2014-01-09 Strategic Science & Technologies, Llc Methods and systems for treatment of migraines and other indications
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
CN111349061B (zh) * 2018-12-21 2022-09-06 河北圣泰材料股份有限公司 四氢噻喃-4-酮1,1-二氧化物的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3483893B2 (ja) * 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018796A1 (de) 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050282857A1 (en) 2004-04-15 2005-12-22 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
CN101146799A (zh) * 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
KR20080056252A (ko) 2008-06-20
AU2006296541A1 (en) 2007-04-05
TW200800922A (en) 2008-01-01
US20090253680A1 (en) 2009-10-08
WO2007036532A2 (de) 2007-04-05
US7897603B2 (en) 2011-03-01
CA2623156A1 (en) 2007-04-05
RU2008116320A (ru) 2009-11-10
EP1931647A2 (de) 2008-06-18
JP2009510022A (ja) 2009-03-12
EP1770086A1 (de) 2007-04-04
ZA200800431B (en) 2009-05-27
CN101273021A (zh) 2008-09-24
US20070072847A1 (en) 2007-03-29
US7582625B2 (en) 2009-09-01
WO2007036532A3 (de) 2007-06-21
IL190423A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
AR056205A1 (es) Antagonistas de receptores cgrp, composiciones farmaceuticas que los contienen, metodo de preparacion y usos para el tratamiento agudo y preventivo de dolores de cabeza, en particular migranas, y otras enfermedades
AR053344A1 (es) Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades
AR081337A1 (es) Derivados de 1,4-benzotiazepinas, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de trastornos metabolicos
AR110434A2 (es) Compuestos de naftalenisoxazolina para el control de plagas de invertebrados
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ECSP066667A (es) Derivados de ciclohexano espirociclicos
AR050963A1 (es) Derivados bis-azaindolicos, su utilizacion farmaceutica como inhibidores de cinasas y su uso en la fabricacion de medicamentos para el tratamiento de los canceres.
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
AR080326A1 (es) Tienipirimidinas que contienen cicloalquilo para composiciones farmaceuticas
AR056460A1 (es) ANTAGONISTAS DE CGRP SELECCIONADOS, PROCEDIMIENTOS PARA SU PREPARACIoN, ASI COMO SU USO COMO MEDICAMENTOS
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida
AR074453A1 (es) Compuestos 4-(azacicloalquil ) benceno-1,3-diol, como inhibidores de la tirosinasa y su uso en medicina humana y tambien en cosmetica
AR086773A1 (es) Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo
AR043444A1 (es) Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2
AR061377A1 (es) Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares.
AR117951A1 (es) Derivados de triazolquinoxalina adicionalmente sustituidos
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR058398A1 (es) Diazepinonas, procesos de obtencion , composiciones farmaceuticas y su uso como inhibidores de quinasas.
AR040078A1 (es) Diaminotiazoles
AR056165A1 (es) 1-benzil-4-piperidinaminas utiles para tratar enfermedades pulmonares
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
UY29883A1 (es) Nuevos beta-agonistas que contienen indol, procedimientos para prepararlos, y su empleo como medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure